
    
      HSCT survivors are at an increased risk for premature aging. No one has evaluated the
      biologic markers of premature aging and senescence in HSCT survivors and their correlation
      with clinical outcomes, lifestyle, and nutrition. The investigators will evaluate age-related
      changes in HSCT survivors, with specified measures of premature aging, and employ therapeutic
      opportunities based on targeting senescent cells by conducting the first in-human pilot study
      of senolytic drugs (in HSCT survivors utilizing a combination of senolytics).
    
  